{"entity":{"id":"nct06413745","kind":"trial","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of Trastuzumab rezetecan in biliary tract cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT06413745 by Jiangsu HengRui Medicine Co., Ltd., with 59 participants enrolled, started 2024-06-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: SHR-A1811.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06413745","url":"https://clinicaltrials.gov/study/NCT06413745"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["trastuzumab-rezetecan"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06413745","phase":"2","setting":"A Phase II Clinical Study of SHR-A1811 in Patients With HER2-expressing/Amplified, Locally Advanced, Unresectable or Metastatic Biliary Tract Cancer (BTC) Who Have Previously Failed First or Second-line Systemic Therapy","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT06413745","source":"https://clinicaltrials.gov/study/NCT06413745","fetchedAt":"2026-10-07T16:54:38.047Z","studySha256":"22b3ffbd5c0bcedeca58995d3a9ecb2a893df69eced20334c29447e7d8d6044e","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-17","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":59,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-06-04","startedType":"actual","enrolled":59,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06413745/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}